A traditional Chinese medicine composition for treating interstitial lung disease and application thereof

Abstract

The application discloses a traditional Chinese medicine composition and application of the traditional Chinese medicine composition in preparation of a medicine for treating interstitial lung disease. The traditional Chinese medicine composition is prepared from raw medicinal materials in the following proportions by weight: 5-25 parts of purple bell, 1-15 parts of ginseng, 1-20 parts of poria cocos, 1-5 parts of pseudo-ginseng, 1-15 parts of angelica sinensis, 1-10 parts of schisandra chinensis, 1-15 parts of anemarrhena asphodeloides, 1-5 parts of cassia bark and 1-15 parts of dried tangerine or orange peel.

Description

Technical Field

[0001] This invention relates to a traditional Chinese medicine composition and its application, specifically to a traditional Chinese medicine composition for treating interstitial lung disease and its application. Background Technology

[0002] Interstitial lung disease (ILD) and pulmonary fibrosis are complex respiratory diseases, clinically characterized by exertional dyspnea, shortness of breath on exertion, dry cough, and wheezing. The disease primarily affects the pulmonary interstitium, involving alveolar epithelial cells, pulmonary capillaries, and pulmonary arteries and veins. Complex pathogenic factors lead to alveolitis, and excessive immune inflammatory responses result in over-repair of interstitial fibrosis, ultimately leading to pulmonary scarring and lung tissue destruction, causing significant gas exchange difficulties and eventually respiratory failure. ILD has numerous clinical subtypes with complex primary and secondary symptoms, and its diverse pathogenesis greatly complicates accurate clinical diagnosis and patient medication. Currently, only bifenidone and nintedanib are approved drugs for treating ILD, which can only relieve clinical symptoms and cannot stop disease progression. Therefore, there is an urgent need to develop safe and effective anti-pulmonary fibrosis drugs. Summary of the Invention

[0003] To address the problems existing in the prior art, this application provides a traditional Chinese medicine composition for treating interstitial lung disease and its application.

[0004] The present invention adopts the following technical solution:

[0005] A traditional Chinese medicine composition, wherein the traditional Chinese medicine composition is made from the following traditional Chinese medicine raw materials in parts by weight: 5-25 parts of Aster tataricus, 1-15 parts of ginseng, 1-20 parts of Poria cocos, 1-5 parts of Panax notoginseng, 1-15 parts of Angelica sinensis, 1-10 parts of Schisandra chinensis, 1-15 parts of Anemarrhena asphodeloides, 1-5 parts of cinnamon, and 1-15 parts of dried tangerine peel.

[0006] Preferably, the traditional Chinese medicine composition of the present invention is made from the following traditional Chinese medicine raw materials in parts by weight: 10-20 parts of Aster tataricus, 5-10 parts of ginseng, 5-15 parts of Poria cocos, 1-5 parts of Panax notoginseng, 5-10 parts of Angelica sinensis, 3-10 parts of Schisandra chinensis, 5-10 parts of Anemarrhena asphodeloides, 1-5 parts of Cinnamomum cassia and 5-10 parts of Citrus reticulata peel.

[0007] More preferably, the traditional Chinese medicine composition of the present invention is made from the following traditional Chinese medicine raw materials in parts by weight: 12.5 parts of Aster tataricus, 5 parts of ginseng, 7.5 parts of Poria cocos, 1.5 parts of Panax notoginseng, 5 parts of Angelica sinensis, 3 parts of Schisandra chinensis, 5 parts of Anemarrhena asphodeloides, 1.5 parts of cinnamon, and 5 parts of dried tangerine peel.

[0008] The formula of this invention is as follows: Aster tataricus is the principal herb, used to moisten the lungs, lower qi, resolve phlegm, and stop coughing. Ginseng greatly replenishes vital energy, enhances physical strength, and improves symptoms of qi deficiency; Poria cocos strengthens the spleen and eliminates dampness, reducing internal dampness and phlegm-dampness obstruction; Angelica sinensis and Panax notoginseng replenish blood, invigorate blood circulation, remove blood stasis, improve blood stasis symptoms, and nourish blood. These four herbs serve as assistant herbs. Anemarrhena asphodeloides is added to clear heat and purge fire, nourish yin and moisten dryness; Schisandra chinensis nourishes yin and astringes the lungs, relieving cough and shortness of breath, assisting the principal and assistant herbs in moistening the lungs, stopping cough, and nourishing the lungs and kidneys. Cinnamomum cassia warms yang and dispels cold; Citrus reticulata regulates qi and resolves phlegm, promoting smooth qi flow and improving internal dampness-phlegm obstruction. These herbs serve as guiding herbs. The entire formula is compact and precisely formulated, supporting the body's resistance and eliminating pathogenic factors, forming a comprehensive effect of replenishing qi and nourishing yin, invigorating blood circulation, removing blood stasis, resolving phlegm, and stopping coughing. It addresses the pathogenesis of lung and kidney qi deficiency combined with phlegm-dampness fibrosis, aiming to improve respiratory function, alleviate symptoms, and slow disease progression.

[0009] The present invention further provides a method for preparing the traditional Chinese medicine composition described herein, the method comprising the following steps: crushing ginseng and cinnamon and then decocting them together with aster, poria, notoginseng, angelica, schisandra, anemarrhena and tangerine peel in water, collecting the volatile oil of the traditional Chinese medicine during decoction, collecting the decoction after decoction, filtering and concentrating the decoction to obtain an extract, the extract and the collected volatile oil being the active pharmaceutical ingredients of the traditional Chinese medicine composition.

[0010] The decoction is performed 1-3 times, with the amount of water added each time being 6-10 times the weight of the raw Chinese medicine. The filtrate is concentrated to the point that each gram of extract is equivalent to 0.8-2.5g of raw herb.

[0011] The traditional Chinese medicine composition described in this invention is a pharmaceutical preparation that can be taken orally, including active pharmaceutical ingredients.

[0012] Preferably, the traditional Chinese medicine composition of the present invention is an oral preparation or a topical preparation.

[0013] In preparing the traditional Chinese medicine composition of the present invention, especially in the process of preparing pharmaceutical formulations, pharmaceutically acceptable excipients may be added as needed, including: fillers, disintegrants, lubricants, suspending agents, binders, sweeteners, flavoring agents, preservatives, matrix, etc.

[0014] The fillers include: starch, pregelatinized starch, lactose, mannitol, chitosan, microcrystalline cellulose, sucrose, etc.

[0015] The disintegrants include: starch, pregelatinized starch, microcrystalline cellulose, sodium carboxymethyl starch, croscarmellose, low-substituted hydroxypropyl cellulose, croscarmellose sodium, etc.

[0016] The lubricants include: magnesium stearate, sodium dodecyl sulfate, talc, silicon dioxide, etc.

[0017] The suspending agents include: polyvinylpyrrolidone, microcrystalline cellulose, sucrose, agar, hydroxypropyl methylcellulose, etc.

[0018] The adhesives include starch paste, polyvinylpyrrolidone, hydroxypropyl methylcellulose, etc.

[0019] The traditional Chinese medicine composition disclosed in this invention can significantly reduce pathological indicators related to inflammation, effectively reduce the inflammatory and fibrotic area in lung tissue, protect the morphology and function of the lungs, and has a therapeutic effect on respiratory diseases induced by inflammation, especially interstitial lung disease. It also has a significant effect on the treatment of interstitial lung disease inflammation and fibrotic interstitial lung disease, and can slow down the progression of fibrotic interstitial lung disease. Attached Figure Description

[0020] Figure 1 The study measured the total cell concentration and inflammatory cell concentration in the bronchoalveolar lavage fluid (BALF) of mice in the normal control group, model control group, and traditional Chinese medicine compound group. The traditional Chinese medicine compound group, which is the traditional Chinese medicine composition group of this invention, was compared with the normal control group. ### P<0.001; compared with the model control group, * P<0.05

[0021] Figure 2 This study measured the concentrations of IL-1β, IL-6, and TNF-α inflammatory factors in the bronchoalveolar lavage fluid (BALF) of mice in the normal control group, model control group, and traditional Chinese medicine compound group. The traditional Chinese medicine compound group, which is the traditional Chinese medicine composition group of this invention, was compared with the normal control group. ### P<0.001; compared with the model control group, *** P<0.001

[0022] Figure 3 This is a statistical analysis of the inflammatory and fibrotic area in the lungs of mice in the normal control group, model control group, and traditional Chinese medicine compound group. The traditional Chinese medicine compound group is the group containing the traditional Chinese medicine composition of this invention. Compared with the normal control group, ### P<0.001; compared with the model control group, * P<0.05

[0023] Figure 4 These are panoramic images of HE-stained lung tissue from mice in the normal control group, model control group, and traditional Chinese medicine compound group. The traditional Chinese medicine compound group is the traditional Chinese medicine composition group of this invention. Detailed Implementation

[0024] The present invention is further illustrated by the following examples, but these are not intended to limit the invention.

[0025] Example 1: Preparation of the traditional Chinese medicine composition 1 of the present invention

[0026] prescription:

[0027] Aster tataricus 25g, Ginseng 10g, Poria cocos 15g, Panax notoginseng 3g, Angelica sinensis 10g, Schisandra chinensis 6g, Anemarrhena asphodeloides 10g, Cinnamomum cassia 3g, Citrus reticulata 10g

[0028] Preparation method: Ginseng and cinnamon are crushed and then decocted with Aster tataricus, Poria cocos, Panax notoginseng, Angelica sinensis, Schisandra chinensis, Anemarrhena asphodeloides and Citrus reticulata peel 1-2 times, while collecting the volatile oil. Each time the decoction is decocted, 6-10 times the amount of water is added. The decoction is filtered, the filtrates are combined, and the filtrates are concentrated to the point that each gram of extract is equivalent to 2.5g of raw herbs. The extract is then mixed with the volatile oil to obtain the final product.

[0029] Example 2: Preparation of the traditional Chinese medicine composition 2 of the present invention

[0030] prescription:

[0031] 20g Aster tataricus, 10g Ginseng, 15g Poria cocos, 5g Panax notoginseng, 10g Angelica sinensis, 10g Schisandra chinensis, 10g Anemarrhena asphodeloides, 5g Cinnamomum cassia, 10g Citrus reticulata peel

[0032] Preparation method: Ginseng and cinnamon are crushed and then decocted with Aster tataricus, Poria cocos, Panax notoginseng, Angelica sinensis, Schisandra chinensis, Anemarrhena asphodeloides and Citrus reticulata peel 1-2 times, while collecting the volatile oil. Each time the decoction is decocted, 6-10 times the amount of water is added. The decoction is filtered, the filtrates are combined, and the filtrates are concentrated to the point that each gram of extract is equivalent to 2.0g of raw herbs. The extract is then mixed with the volatile oil to obtain the final product.

[0033] Example 3: Preparation of the traditional Chinese medicine composition 3 of the present invention

[0034] prescription:

[0035] Aster tataricus 20g, Ginseng 12g, Poria cocos 10g, Panax notoginseng 2g, Angelica sinensis 14g, Schisandra chinensis 10g, Anemarrhena asphodeloides 14g, Cinnamomum cassia 2g, Citrus reticulata 16g

[0036] Preparation method: Ginseng and cinnamon are crushed and then decocted with Aster tataricus, Poria cocos, Panax notoginseng, Angelica sinensis, Schisandra chinensis, Anemarrhena asphodeloides and Citrus reticulata peel 1-2 times, while collecting the volatile oil. Each time the decoction is decocted, 6-10 times the amount of water is added. The decoction is filtered, the filtrates are combined, and the filtrates are concentrated to the point that each gram of extract is equivalent to 1.4g of raw herbs. The extract is then mixed with the volatile oil to obtain the final product.

[0037] Example 4: Preparation of the traditional Chinese medicine composition 4 of the present invention

[0038] prescription:

[0039] Aster tataricus 25g, Ginseng 15g, Poria cocos 20g, Panax notoginseng 5g, Angelica sinensis 15g, Schisandra chinensis 10g, Anemarrhena asphodeloides 15g, Cinnamomum cassia 5g, Citrus reticulata 15g

[0040] Preparation method: Ginseng and cinnamon are crushed and then decocted with Aster tataricus, Poria cocos, Panax notoginseng, Angelica sinensis, Schisandra chinensis, Anemarrhena asphodeloides and Citrus reticulata peel 1-2 times, while collecting the volatile oil. Each time the decoction is decocted, 6-10 times the amount of water is added. The decoction is filtered, the filtrates are combined, and the filtrates are concentrated to the point that each gram of extract is equivalent to 0.8g of raw herbs. The extract is then mixed with the volatile oil to obtain the final product.

[0041] Example 5: Preparation of the traditional Chinese medicine composition 5 of the present invention

[0042] prescription:

[0043] 25g Aster tataricus, 5g Ginseng, 5g Poria cocos, 5g Panax notoginseng, 5g Angelica sinensis, 5g Schisandra chinensis, 5g Anemarrhena asphodeloides, 5g Cinnamomum cassia, 5g Citrus reticulata peel

[0044] Preparation method: Ginseng and cinnamon are crushed and then decocted with Aster tataricus, Poria cocos, Panax notoginseng, Angelica sinensis, Schisandra chinensis, Anemarrhena asphodeloides and Citrus reticulata peel 1-2 times, while collecting the volatile oil. Each time the decoction is decocted, 6-10 times the amount of water is added. The decoction is filtered, the filtrates are combined, and the filtrates are concentrated to the point that each gram of extract is equivalent to 1.0g of raw herbs. The extract is then mixed with the volatile oil to obtain the final product.

[0045] Example 6: Preparation of Capsules

[0046] The extracts prepared in Examples 1-5 were dried and mixed with volatile oils, and appropriate excipients or additives were added. The mixture was then granulated, dried, fully mixed, and filled.

[0047] Experimental Example 1: The therapeutic effect of the composition of the present invention on pulmonary fibrosis

[0048] 1. Materials and Methods

[0049] 1.1 Materials

[0050] 1.1.1 Animals: Forty-five SPF-grade male C57BL / 6 mice, 6-8 weeks old, were purchased from Beijing Vital River Animal Laboratory Technology Co., Ltd., Animal Certificate No.:

[0051] NO.110011241110667382. The animal was housed in the SPF-grade animal facility of Tianjin Pharmaceutical Technology Co., Ltd., with room temperature of 23–25℃, humidity of 40%–60%, and standard feed. The animal had free access to food and water and underwent an acclimatization period of 3 days.

[0052] 1.1.2 Drugs and Reagents: The drugs and reagents used in this invention were prepared according to Example 1. Based on the "Equivalent Dose Ratio Table for Humans and Animals Based on Body Surface Area", the clinical dose was converted to a mouse dosage of 12.61 g / kg, which was used as the dosage in this experiment.

[0053] Bleomycin hydrochloride for injection was purchased from Nippon Kayaku Co., Ltd. (batch number: 340840); interleukin-1β (IL-1β; batch number: 120228003184421202), interleukin-6 (IL-6; batch number: 12022700202681202), and tumor necrosis factor-α (TNF-α; batch number: 120228003104841202) were all purchased from Jianglai Biotechnology.

[0054] 1.1.3 Instruments: Semi-automatic rotary microtome, Leica GmbH, Germany (model: HistoCoreMULTICUT); Tissue embedding machine, Leica GmbH, Germany (model: HistoCore Arcadia);

[0055] Tissue dehydrator, Leica GmbH (model: HistoCore Pearl), Germany; Fully automated staining machine, Leica GmbH (model: ST5010), Germany; Upright microscope, Nikon Corporation (model: ...).

[0056] Ci-L); Inverted microscope, Nikon Corporation (model: TS2); Countstar fully automated cell counter (model: Countstar BioTech); Mutiskan FC basic microplate reader, Thermo

[0057] (Model: 51119080); Fully automated slice scanner, 3D Histech (Model: PannoramicMIDI).

[0058] 1.2 Grouping and Modeling: C57BL / 6 mice were randomly divided into three groups using a random number table: normal control group, model control group, and traditional Chinese medicine compound group, with 15 mice in each group.

[0059] A mouse model of pulmonary fibrosis was established using bleomycin intratracheal injection: Mice were weighed, and anesthesia and the required dosage were calculated based on body weight. Anesthetized mice were placed in a supine position with their trunks fixed, necks exposed, and disinfected with alcohol. Neck hair was removed with a scalpel. An incision of approximately 0.5 cm was made along the midline of the neck. The neck muscles were separated with forceps to expose the trachea. An appropriate dose of bleomycin solution was drawn using an insulin injection needle and injected into the lungs via the trachea. Normal controls received saline injections into the trachea. The mice were then gently patted on the back to ensure even distribution of the bleomycin. The incision was sutured, and local skin treatment was applied to prevent infection.

[0060] 1.3 Intervention Administration Method: The dosage for mice was calculated based on the "Equivalent Dose Ratio Table for Humans and Animals Based on Body Surface Area," converting the clinical dose to the mouse dosage. The dosage for the traditional Chinese medicine compound group was the daily raw drug intake for mice.

[0061] 12.61 g / kg was used to prepare a drug solution with a concentration of 0.68 g / mL. Mice in the traditional Chinese medicine compound group were administered the corresponding drug solution by gavage at a dose of 0.2 mL / 10 g daily, while the normal control group and the model control group were administered physiological saline by gavage at the same dose. The intervention for all groups of mice began on the first day after modeling and continued once daily until the end of the experiment for a total of 7 days.

[0062] 1.4 Detection Indicators and Methods

[0063] 1.4.1 Detection of total cell count in bronchoalveolar lavage fluid: The limbs of mice were fixed in a supine position, the skin of the mice was cut open with small scissors to expose the organs and trachea, the tracheal tube was inserted into the trachea, and PBS was drawn up with a syringe for lavage twice. The lavage fluid was placed in EP tubes, centrifuged and stored, and the precipitate was used for total cell count and inflammatory cell count.

[0064] 1.4.2 Expression of inflammatory factors in bronchoalveolar lavage fluid: The expression of inflammatory factors IL-6, TNF-α, and IL-1β in the supernatant of bronchoalveolar lavage fluid was detected using an ELISA kit, and the detection was performed according to the instructions.

[0065] 1.4.3 Lung Fibrosis Area: The left lung of mice was fixed in formalin for 24-48 hours, then placed in an embedding cassette and dehydrated in an automated dehydrator according to a set program. The next day, it was embedded in paraffin. Paraffin sections were prepared using a semi-automatic rotary microtome, with a section thickness of 5 μm. Glass slides were placed in an automated staining machine for H&E staining. After staining, the slides were removed, and a suitable amount of neutral resin was added for mounting. The prepared sections were trimmed and photographed using a pathological slide scanner. After photographing, the fibrosis area was calculated using dedicated image viewing software.

[0066] 1.4.4 Statistical Methods Quantitative data are expressed as x±s. If the data conform to a normal distribution and satisfy homogeneity of variance, one-way ANOVA is used for comparisons among multiple groups. If the data are skewed or do not satisfy homogeneity of variance, a nonparametric test with rank transformation is used. A p-value < 0.05 is considered statistically significant.

[0067] 2 Results

[0068] 2.1 Cell Count Detection in Bronchoalveolar Lavage Fluid: The mean cell concentration in the normal control group was 0.35*10^6, the mean cell concentration in the model control group was 5.14*10^6 after the end of administration, and the mean cell concentration in the traditional Chinese medicine compound group was 2.80*10^6 after administration. Treatment with the traditional Chinese medicine compound significantly reduced the total number of lung cells induced by BLM. The total cells were classified and counted, including monocytes / macrophages, lymphocytes, and neutrophils. The results showed that the concentrations of all three cell types in the bronchoalveolar lavage fluid significantly increased after BLM modeling. Relapse of the traditional Chinese medicine treatment reduced cell concentrations to varying degrees, with significant differences observed in neutrophils and lymphocytes (see Table 1). Figure 1 ).

[0069] Table 1. Detection of total cell and inflammatory cell concentrations in mouse BALF

[0070]

[0071] Note: Compared with the normal control group, ### P<0.001; compared with the model control group, * P<0.05

[0072] 2.2 Detection of inflammatory factors in bronchoalveolar lavage fluid: The average IL-6 concentration in the control group mice after the end of administration was 638.92 pg / ml, which was significantly higher than the 263.27 pg / ml in the normal control group. The average IL-6 concentration in the traditional Chinese medicine compound group after administration was 288.54 pg / ml, which could significantly reduce the IL-6 concentration in bronchoalveolar lavage fluid induced by BLM.

[0073] In the model control group, the average IL-1β concentration was 112.14 pg / ml after the end of drug administration, significantly higher than the 27.94 pg / ml in the normal control group. In the traditional Chinese medicine compound group, the average IL-1β concentration was 21.37 pg / ml after drug administration. The traditional Chinese medicine compound significantly reduced the IL-1β concentration in BLM-induced bronchoalveolar lavage fluid.

[0074] The average TNF-α concentration in the model control group mice after the end of drug administration was 181.34 pg / ml, significantly higher than the 75.15 pg / ml in the normal control group. The average TNF-α concentration in the traditional Chinese medicine compound group after drug administration was 82.20 pg / ml, which significantly reduced the TNF-α concentration in BLM-induced lung lavage fluid (see Table 2). Figure 2 ).

[0075] Table 2. Detection of inflammatory factor concentrations in mouse BALF

[0076]

[0077]

[0078] Note: Compared with the normal control group, ### P<0.001; compared with the model control group, *** P<0.001

[0079] 2.3 Statistical Analysis of Lung Tissue Inflammatory Fibrosis Area After BLM modeling, significant inflammatory cell infiltration and extracellular matrix deposition occurred in the lungs. The inflammatory fibrosis area was statistically analyzed in tissue sections. The results showed that the average inflammatory fibrosis area in the control group was 11.95% after the end of drug administration, while the average inflammatory fibrosis area in the traditional Chinese medicine compound group was 6.10% after the end of drug administration. The traditional Chinese medicine compound significantly reduced the area of ​​BLM-induced lung inflammatory fibrosis (see Table 3). Figure 3 , Figure 4 ).

[0080] Table 3. Area of ​​inflammatory fibrosis in the lungs of mice

[0081]

[0082] Note: Compared with the normal control group, ### P<0.001; compared with the model control group, * P<0.05

[0083] In summary, the traditional Chinese medicine compound of this invention can significantly reduce the concentrations of total cells, neutrophils, and lymphocytes in mouse BALF, as well as inflammation-related pathological indicators such as inflammatory factors IL-6, TNF-α, and IL-1β. Simultaneously, it can effectively reduce the area of ​​inflammatory fibrosis in lung tissue, protecting the morphology and function of the lungs. In conclusion, the traditional Chinese medicine compound of this invention can exert a good anti-inflammatory effect and effectively alleviate the progression of pulmonary fibrosis in interstitial lung disease.

Claims

1. A traditional Chinese medicine composition for treating interstitial lung disease, characterized in that, The traditional Chinese medicine composition is made from the following traditional Chinese medicine raw materials in parts by weight: 5-25 parts of Aster tataricus, 1-15 parts of ginseng, 1-20 parts of Poria cocos, 1-5 parts of Panax notoginseng, 1-15 parts of Angelica sinensis, 1-10 parts of Schisandra chinensis, 1-15 parts of Anemarrhena asphodeloides, 1-5 parts of cinnamon, and 1-15 parts of dried tangerine peel.

2. The traditional Chinese medicine composition according to claim 1, characterized in that, The traditional Chinese medicine composition is made from the following traditional Chinese medicine raw materials in parts by weight: 10-20 parts of Aster tataricus, 5-10 parts of ginseng, 5-15 parts of Poria cocos, 1-5 parts of Panax notoginseng, 5-10 parts of Angelica sinensis, 3-10 parts of Schisandra chinensis, 5-10 parts of Anemarrhena asphodeloides, 1-5 parts of Cinnamomum cassia and 5-10 parts of Citrus reticulata peel.

3. The traditional Chinese medicine composition according to claim 1, characterized in that, The traditional Chinese medicine composition is made from the following parts by weight of raw materials: 12.5 parts of Aster tataricus, 5 parts of ginseng, 7.5 parts of Poria cocos, 1.5 parts of Panax notoginseng, 5 parts of Angelica sinensis, 3 parts of Schisandra chinensis, 5 parts of Anemarrhena asphodeloides, 1.5 parts of cinnamon, and 5 parts of dried tangerine peel.

4. The preparation method of the traditional Chinese medicine composition according to any one of claims 1-3, characterized in that, The method includes the following steps: Ginseng and cinnamon are crushed and then decocted together with Aster tataricus, Poria cocos, Panax notoginseng, Angelica sinensis, Schisandra chinensis, Anemarrhena asphodeloides and Citrus reticulata. The volatile oil of the Chinese medicine is collected during the decoction. The decoction is collected after decoction and then filtered and concentrated to obtain an extract. The extract and the collected volatile oil are the active pharmaceutical ingredients of the Chinese medicine composition.

5. The production method according to claim 4, characterized by, The decoction is performed 1-3 times, with the amount of water added each time being 6-10 times the weight of the raw Chinese medicine.

6. A pharmaceutical preparation for treating interstitial lung disease, characterized by comprising, Includes the traditional Chinese medicine composition according to any one of claims 1-3.

7. The traditional Chinese medicine preparation according to claim 6, characterized in that, The traditional Chinese medicine preparation mentioned is an oral preparation.

8. Use of the traditional Chinese medicine composition according to any one of claims 1-3 in the preparation of a medicament for treating interstitial lung disease.

9. The use according to claim 8, wherein the interstitial lung disease includes interstitial lung disease with inflammation and / or fibrotic interstitial lung disease.

10. Use of the traditional Chinese medicine composition according to any one of claims 1-3 in the preparation of a medicament for delaying the progression of fibrotic interstitial lung disease.

Images